Geron Corporation

Jim Cramer takes a closer look at Box, Applied Materials, Goodyear, Geron, Cognex, Jacobs Engineering, Editas Medicine.

Expectations about earnings are totally out of whack, says Jim Cramer. Will Apple's earnings break the spell?

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

Geron and Endo and were among the biotech stock movers on Aug. 1.

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

Innoviva, Akebia Therapeutics and Geron were among the biotech stock movers in premarket trading on Tuesday.

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Geron (GERN) announced on Monday that it agreed to a licensing deal with Janssen Pharmaceuticals worth $80 million.

Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate

Trade-Ideas LLC identified Geron (GERN) as a weak on high relative volume candidate

Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate

Cramer awaits this week's earnings from H&R Block, Costco and Adobe Systems, among other companies.

Cramer picks Verizon or AT&T over Frontier Communications and Biogen Idec or Celgene over Geron.

Trade-Ideas LLC identified Geron (GERN) as a weak on high relative volume candidate

Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate

Trade-Ideas LLC identified Geron (GERN) as a "perilous reversal" (up big yesterday but down big today) candidate

Cramer prefers Dominion Resources D to Pepco Holding POM and is sticking with Energy Transfer Partners ETP.

As we begin the third full week of trading in the back half of 2022, these issues should be receiving greater play.

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

Financial stocks took the brunt of this week's difficult market action, and we remain in wait-and-see mode.

We made several moves in the model portfolio this week, including initiating two new positions and closing another.

During a busy week for the model portfolio, we added a new holding and saw two names report strong earnings results.

Two of our model portfolio holdings in the sector are up today. Also, we added three new names to the Watch List.

A busy week for the model portfolio included the closing of two positions.

The data-rich week brought more positives for the market and the model portfolio.

It was a quiet but very positive week for most of our holdings.

Several factors set this new name apart from its peers.

Earnings season kicked into high gear this week, and the model portfolio saw the addition of one new name.

With no new catalysts in sight, we're selling this stock into strength.

News like this morning's announcement should spur interest in this name, and we're holding firm.

Stocks finished in positive territory this week, and three new names joined the model portfolio.

The recent news flow in this stock may be peaking, so we're booking some profits.

The move in this stock is real, even if the catalysts might be suspect.

These four stocks are showing some gains. Here's our take.

This biotech gets FDA approval to begin clinical trials for its lead drug.

Some announcements are boosting two holdings. Here's our take.

Mark Zuckerberg's AI team unveiled big plans for AI in an email chain

These 10 compact and midsized sport utility vehicles earned CR’s highest marks, and they sell for wallet-friendly prices.

Here’s what could be next in the AI boom.